Anti-tumor immunotherapy against multidrug resistance;Immunothérapie anti-tumorale contre la multidrogue résistance

Annales Pharmaceutiques Francaises

Volumn 64, Issue 2, 2006, Pages 87-96

  Madoulet, Cl ^a   Perrin, L ^a   Tosi, P F ^a   Albert, P ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Immunization; Lipopeptides; Liposome; Multidrug resistance (MDR); P Glycoprotein 170 kDa (P170)

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AUTOANTIBODY; DOXORUBICIN; GLYCOPROTEIN; GLYCOPROTEIN GP 170; GLYCOPROTEIN P; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; LIPID A; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VINBLASTINE; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; GENE OVEREXPRESSION; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PALMITOYLATION; SURVIVAL RATE; SURVIVAL TIME; ANIMAL; DRUG RESISTANCE; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA P 388; NEOPLASM; TUMOR CELL LINE;

ANIMALS; AUTOANTIBODIES; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY; LEUKEMIA P388; LIPOSOMES; MICE; NEOPLASMS;

EID: 33646271833     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4509(06)75300-7     Document Type: Article

References (43)

1. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989 ; 58 : 137-71.
2. Moscow JA, Cowan KH. Multidrug resistance. Cancer Chemother Biol Resp Modif 1990 ; 21 : 97-114.
3. Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM et al. Internal duplication and homology with bacterial transport proteins in the mdr-1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986 ; 47 : 381-9.
4. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990 ; 10 : 1652-63.
5. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce RS et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990 ; 346 : 362-5.
6. Roninson IB. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 1992 ; 43 : 95-104.
7. Hegmann EJ, Bauer HC, Kerbel RS. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res 1992 ; 52 : 6969-75.
8. Schinkel AH, Smit JJ, Van Tellingen O, Beijnen JH, Wagenaar E, Van Deemter L. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994 ; 77 : 491-502.
9. Schinkel AH, Arceci RJ, Smit JJ, Wagenaar E, Baas F, Dolle M et al. Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. Int J Cancer 1993 ; 30 : 55 (3), 478-84.
10. Mechetner EB, Roninson IB, Efficient inhibition of P-glycoprotein mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992 ; 89 : 5824-8.
11. Gros PH, Croop J, Housman D. Mammalian drug resistance gene : complete cDNA sequence indicates a strong homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 1986 ; 47 : 371-80.
12. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, Van Deemter L et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993 ; 75 : 451-62.
13. Tosi PF, Radu D, Nicolau C. Immune response against the murine mdr1 protein induced by vaccination with synthetic lipopeptides in liposomes. Biochem Biophys Res Com 1995 ; 212 : 2, 494-500.
14. Nicolau C, Greferath R, Balaban ST, Lazarte JE, Hopkins RJ. A liposome-based therapeutic vaccine against β-amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci 2002 ; 99 : 4, 2332-42.
15. Richards RL, Hayre MD, Hockmeyzr WT, Alving CR. Liposomes, lipid A and aluminium hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun 1988 ; 56 : 682-6.
16. Gros P, Buschman E. The mouse multidrug resistance gene family : Structural and functional analysis. Int Rev Cyto 1993 ; 137C : 169-97.
17. Merrifield RB. Solid phase peptide synthesis. The synthesis of a tetrapeptide. J Am Chem Soc 1963 ; 85 : 2149-54.
18. Merrifield RB. Solid phase synthesis. Science 1986 ; 232 : 341.
19. Schnölzer M, Alewood P, Jones A, Alewood D, Kent SBH. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Int J Peptide Protein Res 1992 ; 40 : 180-93.
20. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M et al. Liposomal malaria vaccine in humans : a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 1992 ; 89 : 358-62.
21. Jiao H, Shen W, Ohe Y, Miura K, Tamura T, Saijo N. A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro. Cancer Immunol Immunother 1992 ; 35 : 412-6.
22. Grant S, Rausher F, Jakubowski A, Cadman E. Effect of N-(phosphonacetyl)-L-aspartate on S-azacytidine metabolism in P388 and L1210 cells. Cancer Res 1981 ; 41 : 410-4.
23. Lum BL, Gosland MP, Kaibish S, Sikic BI. Molecular targets in oncology : implications of the multidrug resistance gene. Pharmacotherapy 1993 ; 13 : 88-109.
24. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990 ; 42 : 155-99.
25. Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R et al. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer 1990 ; 65 : 1895-902.
26. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. Clin Oncol 1992 ; 10 : 1730-6.
27. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent : phase I trial in combination with vinblastine. J Natl Cancer Inst 1992 ; 84 : 1811-6.
28. Beck WT, Danks MF. In: Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells (Roninson IB, Ed) 1991, 3-55, Plenum Press, New York.
29. Hebell T, Ahearn JM, Fearon DT. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 1991 ; 254 : 102-5.
30. Swartz GM Jr, Gentry MK, Amende LM, Blanchette-Mackie EJ, Alving CR. Antibodies to cholesterol. Proc Natl Acad Sci USA 1988 ; 85 : 1902-6.
31. Edelman R. Vaccine adjuvants. Rev Infed Dis 1980 ; 2 : 370-83.
32. Watari E, Dietzschold B, Szokan D, Heber-Katz E. A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2. J Exp Med 1987 ; 165 : 459-70.
33. Deres K, Schilf H, Wiesmüller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989 ; 342 : 561-4.
34. Bourgault I, Chirat F, Tartar A, Levy JP, Guillet JG, Venet A. Simian immunodeficiency virus as a model for vaccination against HIV. J Immunol 1994 ; 152 : 2530-7.
35. Miller TP, Grogan TM, Dalton WSN, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991 ; 9 : 17-24.
36. Pierré A, Dunn TA, Kraus-Berthier L, Leonce S, Saint-Dizier D, Regnier G et al. In vitro and in vivo circumvention of multidrug resistance by servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drug 1992 ; 10 : 137-48.
37. Beck WT. Do anti-P-glycoprotein antibodies have a future in the circumvention of multidrug resistance? J Natl Cancer Inst 1991 ; 83 : 19, 1364-6.
38. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993 ; 62 : 385-427.
39. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Tsuruo T, Pinedo HM, Lankelma J. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein. Biochem Pharmacol 1988 ; 37 : 12, 2389-93.
40. Chan HSL, Grogan TM, Haddad G, Deboer G, Ling VP. P-glycoprotein expression : critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 1997 ; 89 : 22, 1706-15.
41. Efferth T, Volm M. Antibody-directed therapy of multidrug-resistant tumor cells. Med Oncol Tumor Pharmacother 1992 ; 9 : 1, 11-9.
42. Cole SPC, Bhardwaj G, Gerlach JH, Machie JE, Grant CE, Almquist KCN et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992 ; 258 : 1650-4.
43. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al. Phase II study of weekly intravenous recombinant humanised anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast. J Clin Oncol 1996 ; 14 : 737-44.